Insight Report 6 minutes PremiumWhat the Ozempic Economy Means for US Retail Anand Kumar, Associate Director of Retail Research Sector Lead: Swarooprani Muralidhar, Director of Research November 20, 2023 What's InsideOzempic, a medication used to treat type 2 diabetes, is gaining strong momentum in the pharmaceutical market due to its ability to manage blood sugar levels and promote weight loss. The increased adoption of Ozempic and other drugs in the GLP-1 drug class reflects a broader consumer shift toward prioritizing health and wellness. We dive into the implications of widespread GLP-1 drug use on US retail, including the impacts on sectors such as grocery and apparel. Companies mentioned in this report include: Hershey, Lululemon Athletica, Mondelēz International, NIKE, PepsiCo, Walmart Other relevant research: Weinswig’s Weekly: Health Is Wealth Market Navigator: US Apparel and Footwear Retailing—After the Bounce, What’s Next? Generative AI for US Retail Pharmacies and Healthcare: Satisfying Customers through Automation and Personalization Visit the Coresight Research Food, Grocery and CPG Retail Hub to explore sector data, reports and company profiles. This report is for paying subscribers only. Already a paying subscriber? Please log in to see the entire report.If you wish to learn more about our subscription plans and become a paying subscriber, click here. This document was generated for Other research you may be interested in: Supercharging Manufacturer and Distributor Sales Productivity with Digital CommerceAugust 2023 China Retail Sales: Growth Rate Improves, Breaking Three-Month Downward TrendIs the Future of Security Locked in Technology?: Insights Presented at NRF Protect 2023Ebook: Discount Decades